Abstract
Clinical trials have investigated the benefit of combining chemotherapy and immune checkpoint inhibitors (ICIs) in resectable non-small cell lung cancer (NSCLC) patients has been investigated. Our aim is to synthesize the evidence of efficacy and safety of neoadjuvant chemoimmunotherapy treatment in a systematic review.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
